Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of “Buy” by Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received an average rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $41.20.

BCAX has been the subject of several analyst reports. Wedbush restated an “outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research note on Wednesday. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, HC Wainwright increased their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, January 27th.

Bicara Therapeutics Trading Down 0.8 %

BCAX opened at $13.12 on Friday. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09. The stock’s 50 day moving average price is $15.27.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Equities analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently made changes to their positions in BCAX. First Turn Management LLC purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter worth $14,324,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter worth $582,000. FMR LLC purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter worth $57,913,000. Walleye Capital LLC purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter worth $809,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter worth $10,825,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.